Cardior Pharmaceuticals Alternatives & Competitors
12 companies similar to Cardior Pharmaceuticals — Cardior develops RNA-based therapeutics designed to prevent, repair and reverse...
Companies similar to Cardior Pharmaceuticals
Heartseed Inc.
Clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiom...
Japan
CAMP4 Therapeutics
Advancing a pipeline of ASO-based, RNA-targeting therapeutics with the aim to restore heal...
Cambridge, United States
BlueRock Therapeutics
Striving to transform the treatment of disease by harnessing the power of cell therapy
Cambridge, United States
AusperBio
Transforming Patient Lives For a Better Tomorrow
San Mateo, United States
Rival Readout
Competing with Cardior Pharmaceuticals? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Rampart Bioscience
Leading a new era of effective, safe and accessible gene medicines.
Monrovia, United States
Autotelic Bio Inc.
RNA Therapeutics New Drug Development Company
Korea South
HAYA Therapeutics
Programmable Therapeutics for Causal Biology - Science Guides Us. The Genome Powers Us. P...
Switzerland
Vial
Vial is a next-gen pharma company advancing best-in-class biologics and RNA therapeutics a...
San Francisco, United Sta...
Yuanyin Bio
Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clini...
Cardurion Pharmaceuticals
Translating the science of cardiac myocyte signaling pathways into groundbreaking therapeu...
Burlington, United States
Arrakis Therapeutics
Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to...
Waltham, United States
RIGImmune Inc.
Targeted non-LNP Delivery of RNA Therapeutics
Farmington, United States
About Cardior Pharmaceuticals
Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company, established in 2016, with a focus on the discovery and development of RNA-based therapeutics to address cardiac diseases. Operating from its headquarters in Germany, Cardior leverages distinctive non-coding RNAs to innovate treatments that target th...
Discovery and development of RNA-based therapeutics, Phase 2 Clinical Studies, Transformative treatments for heart diseases
Patients with heart diseases, Healthcare professionals, Cardiology researchers
RNA Therapeutics, Cardiac Disease Treatment, Non-coding RNA, Biopharmaceuticals, Heart Disease Prevention, Clinical-stage Biotechnology, Oligonucleotide-based Inhibitor, MicroRNA, Cardiac Dysfunction, Therapeutic Platform, RNA-based Diagnostics, LncRNA, Cardiovascular Therapeutics, Pathological Alterations
B2B, B2D
Licensing, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Cardior Pharmaceuticals: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Cardior Pharmaceuticals on 28 May 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 2 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
